A TARTOS GONADOTROPIN-RELEASING HORMON (GnRH) ANALOG KEZELES HORMONALIS HATASAI POLYCYSTAS OVARIUM SYNDROMABAN

Translated title of the contribution: Hormonal effects of the long-term gonadotropin-releasing hormone (GnRH) analogue treatment of the polycystic ovary syndrome

A. Szilagyi, J. Homoki, I. Szabó

Research output: Contribution to journalArticle

Abstract

8 patients with polycystic ovary syndrome (PCOS) were treated by a long-acting gonadotropin-releasing hormone (GnRH) analogue (Decapeptyl® depot - Ferring, Germany) for 3 months. A monthly blood sampling was performed for gonadotropic hormone, prolactin, testosterone and estradiol determinations. Urinary steroids were profiled by capillary column gas chromatography prior to and three months following the treatment. Apart from the quantification of the excreted steroids, the ratios of androsterone to etiocholanolone (An/Et) and 5α-tetrahydrocortisol to tetrahydrocortisol (aTHF/THF) were calculated from the urine samples to evaluate the increased 5α-reductase enzyme activity, which is characteristic to PCOS. Furthermore, the ratio of androgenic metabolites to cortisone metabolites (AM/CM) was calculated. AM/CM was normalized and An/Et and aTHF/THF were significantly decreased during the GnRH analogue treatment. Serum LH was suppressed to a value less than 1 IU/l, FSH and prolactin did not change significantly. Serum testosterone was normalized, estradiol decreased to a level characteristic for postmenopausal women. Patients became amenorrheic during the treatment and mild hot flushes were experienced by most of them. The degree of hirsutism decreased, but it was not significant after 3 months' treatment. In conclusion, Decapeptyl depot treatment improves the hyperandrogenic state characteristic for PCOS, and this improvement may be well monitored by gas chromatographic profiling of the urinary steroids. A significant clinical improvement would require a therapy for more than 3 months.

Original languageHungarian
Pages (from-to)381-385
Number of pages5
JournalMagyar Noorvosok Lapja
Volume59
Issue number5
Publication statusPublished - 1996

Fingerprint

Polycystic Ovary Syndrome
Gonadotropin-Releasing Hormone
Tetrahydrocortisol
Etiocholanolone
Triptorelin Pamoate
Androsterone
Steroids
Cortisone
Prolactin
Testosterone
Estradiol
Therapeutics
Oil and Gas Fields
Hirsutism
Serum
Gas Chromatography
Germany
Oxidoreductases
Urine
Hormones

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

A TARTOS GONADOTROPIN-RELEASING HORMON (GnRH) ANALOG KEZELES HORMONALIS HATASAI POLYCYSTAS OVARIUM SYNDROMABAN. / Szilagyi, A.; Homoki, J.; Szabó, I.

In: Magyar Noorvosok Lapja, Vol. 59, No. 5, 1996, p. 381-385.

Research output: Contribution to journalArticle

@article{c9f205aff7c74120a92eb41dd8752576,
title = "A TARTOS GONADOTROPIN-RELEASING HORMON (GnRH) ANALOG KEZELES HORMONALIS HATASAI POLYCYSTAS OVARIUM SYNDROMABAN",
abstract = "8 patients with polycystic ovary syndrome (PCOS) were treated by a long-acting gonadotropin-releasing hormone (GnRH) analogue (Decapeptyl{\circledR} depot - Ferring, Germany) for 3 months. A monthly blood sampling was performed for gonadotropic hormone, prolactin, testosterone and estradiol determinations. Urinary steroids were profiled by capillary column gas chromatography prior to and three months following the treatment. Apart from the quantification of the excreted steroids, the ratios of androsterone to etiocholanolone (An/Et) and 5α-tetrahydrocortisol to tetrahydrocortisol (aTHF/THF) were calculated from the urine samples to evaluate the increased 5α-reductase enzyme activity, which is characteristic to PCOS. Furthermore, the ratio of androgenic metabolites to cortisone metabolites (AM/CM) was calculated. AM/CM was normalized and An/Et and aTHF/THF were significantly decreased during the GnRH analogue treatment. Serum LH was suppressed to a value less than 1 IU/l, FSH and prolactin did not change significantly. Serum testosterone was normalized, estradiol decreased to a level characteristic for postmenopausal women. Patients became amenorrheic during the treatment and mild hot flushes were experienced by most of them. The degree of hirsutism decreased, but it was not significant after 3 months' treatment. In conclusion, Decapeptyl depot treatment improves the hyperandrogenic state characteristic for PCOS, and this improvement may be well monitored by gas chromatographic profiling of the urinary steroids. A significant clinical improvement would require a therapy for more than 3 months.",
keywords = "Gas-chromatography, GnRH analogue, PCOS, Steroids",
author = "A. Szilagyi and J. Homoki and I. Szab{\'o}",
year = "1996",
language = "Hungarian",
volume = "59",
pages = "381--385",
journal = "Magyar Noorvosok Lapja",
issn = "0025-021X",
publisher = "Magyar Noovos Tarsasag",
number = "5",

}

TY - JOUR

T1 - A TARTOS GONADOTROPIN-RELEASING HORMON (GnRH) ANALOG KEZELES HORMONALIS HATASAI POLYCYSTAS OVARIUM SYNDROMABAN

AU - Szilagyi, A.

AU - Homoki, J.

AU - Szabó, I.

PY - 1996

Y1 - 1996

N2 - 8 patients with polycystic ovary syndrome (PCOS) were treated by a long-acting gonadotropin-releasing hormone (GnRH) analogue (Decapeptyl® depot - Ferring, Germany) for 3 months. A monthly blood sampling was performed for gonadotropic hormone, prolactin, testosterone and estradiol determinations. Urinary steroids were profiled by capillary column gas chromatography prior to and three months following the treatment. Apart from the quantification of the excreted steroids, the ratios of androsterone to etiocholanolone (An/Et) and 5α-tetrahydrocortisol to tetrahydrocortisol (aTHF/THF) were calculated from the urine samples to evaluate the increased 5α-reductase enzyme activity, which is characteristic to PCOS. Furthermore, the ratio of androgenic metabolites to cortisone metabolites (AM/CM) was calculated. AM/CM was normalized and An/Et and aTHF/THF were significantly decreased during the GnRH analogue treatment. Serum LH was suppressed to a value less than 1 IU/l, FSH and prolactin did not change significantly. Serum testosterone was normalized, estradiol decreased to a level characteristic for postmenopausal women. Patients became amenorrheic during the treatment and mild hot flushes were experienced by most of them. The degree of hirsutism decreased, but it was not significant after 3 months' treatment. In conclusion, Decapeptyl depot treatment improves the hyperandrogenic state characteristic for PCOS, and this improvement may be well monitored by gas chromatographic profiling of the urinary steroids. A significant clinical improvement would require a therapy for more than 3 months.

AB - 8 patients with polycystic ovary syndrome (PCOS) were treated by a long-acting gonadotropin-releasing hormone (GnRH) analogue (Decapeptyl® depot - Ferring, Germany) for 3 months. A monthly blood sampling was performed for gonadotropic hormone, prolactin, testosterone and estradiol determinations. Urinary steroids were profiled by capillary column gas chromatography prior to and three months following the treatment. Apart from the quantification of the excreted steroids, the ratios of androsterone to etiocholanolone (An/Et) and 5α-tetrahydrocortisol to tetrahydrocortisol (aTHF/THF) were calculated from the urine samples to evaluate the increased 5α-reductase enzyme activity, which is characteristic to PCOS. Furthermore, the ratio of androgenic metabolites to cortisone metabolites (AM/CM) was calculated. AM/CM was normalized and An/Et and aTHF/THF were significantly decreased during the GnRH analogue treatment. Serum LH was suppressed to a value less than 1 IU/l, FSH and prolactin did not change significantly. Serum testosterone was normalized, estradiol decreased to a level characteristic for postmenopausal women. Patients became amenorrheic during the treatment and mild hot flushes were experienced by most of them. The degree of hirsutism decreased, but it was not significant after 3 months' treatment. In conclusion, Decapeptyl depot treatment improves the hyperandrogenic state characteristic for PCOS, and this improvement may be well monitored by gas chromatographic profiling of the urinary steroids. A significant clinical improvement would require a therapy for more than 3 months.

KW - Gas-chromatography

KW - GnRH analogue

KW - PCOS

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=0029758212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029758212&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 381

EP - 385

JO - Magyar Noorvosok Lapja

JF - Magyar Noorvosok Lapja

SN - 0025-021X

IS - 5

ER -